TY - JOUR
T1 - OCT1 polymorphism is associated with response and survival time in anti-Parkinsonian drug users
AU - Becker, Matthijs
AU - Visser, Loes
AU - van Schaik, Ron
AU - Hofman, Bert
AU - Uitterlinden, André
AU - Stricker, Bruno
PY - 2011
Y1 - 2011
N2 - Substrates for the Organic Cation Transporter 1, encoded by the SLC22A1 gene, are metformin, amantadine, pramipexole, and, possibly, levodopa. Recently, we identified that the rs622342 A > C polymorphism is associated with the HbA1c lowering effect in metformin users. In the Rotterdam Study, we associated this polymorphism with higher prescribed doses of all anti-Parkinsonian drugs. Between the first and fifth prescriptions for levodopa, for each minor rs622342 C allele, the prescribed doses were 0.34 defined daily dose higher (95% CI 0.064, 0.62; p = 0.017). The mortality ratio after start of levodopa therapy was 1.47 times higher (95% CI 1.01, 2.13; p = 0.045).
AB - Substrates for the Organic Cation Transporter 1, encoded by the SLC22A1 gene, are metformin, amantadine, pramipexole, and, possibly, levodopa. Recently, we identified that the rs622342 A > C polymorphism is associated with the HbA1c lowering effect in metformin users. In the Rotterdam Study, we associated this polymorphism with higher prescribed doses of all anti-Parkinsonian drugs. Between the first and fifth prescriptions for levodopa, for each minor rs622342 C allele, the prescribed doses were 0.34 defined daily dose higher (95% CI 0.064, 0.62; p = 0.017). The mortality ratio after start of levodopa therapy was 1.47 times higher (95% CI 1.01, 2.13; p = 0.045).
U2 - 10.1007/s10048-010-0254-5
DO - 10.1007/s10048-010-0254-5
M3 - Article
VL - 12
SP - 79
EP - 82
JO - Neurogenetics
JF - Neurogenetics
SN - 1364-6745
IS - 1
ER -